Clinical Trial: Tirzepatide in the Treatment of Cannabis Use Disorder: A Proof-of-Concept Study

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07671248) titled 'Tirzepatide in the Treatment of Cannabis Use Disorder: A Proof-of-Concept Study' on June 15.

Brief Summary: Cannabis is the most commonly used psychoactive substance in Canada (Lowry & Corsi, 2020). A sub-group of cannabis users develop Cannabis Use Disorder (CUD). CUD is a pattern of cannabis use that results in impairment in functioning, symptoms of tolerance, withdrawal, and distress (Hasin et al., 2013). Several pharmacological and psychosocial interventions have been evaluated for their efficacy in treating CUD, however they lack high success rates. GLP-1RA's have shown promising results in reducing food and alcohol cravings an...